Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxycodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 7/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxycodone SCHEMBL3121359 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL12945207 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL12960967 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL618773 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL14394071 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL4104773 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL18410410 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL22058352 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL22163723 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL16015666 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021249708-A1 | PROCESSES FOR PREPARING NOR-OPIOID COMPOUNDS AND OPIOID ANTAGONISTS BY ELECTROCHEMICAL N-DEMETHYLATION | RESEARCH CENTER PHARMACEUTICAL ENGINEERING GMBH (AT) | 2021-12-16 | — | — | WO | disclosed |
| US-20210061815-A1 | NOVEL OPIOID COMPOUNDS AND USES THEREOF | RHODES TECHNOLOGIES (US) | 2021-03-04 | — | — | US | disclosed |
| WO-2021024041-A1 | CONTROLLED RELEASE DRUG DIMERS | RIPPLE THERAPEUTICS CORPORATION (CA) | 2021-02-11 | — | — | WO | disclosed |
| WO-2021024039-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN AND DEPENDANCE DISORDERS | RIPPLE THERAPEUTICS CORPORATION (CA) | 2021-02-11 | — | — | WO | disclosed |
| US-10844072-B2 | Process for improved oxycodone synthesis | RHODES TECHNOLOGIES (US) | 2020-11-24 | — | — | US | disclosed |
| US-10695342-B2 | Methods and compositions for preventing opioid abuse | ALBANY MOLECULAR RESEARCH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200199134-A1 | PROCESS FOR IMPROVED OXYCODONE SYNTHESIS | RHODES TECHNOLOGIES (US) | 2020-06-25 | — | — | US | disclosed |
| WO-2019165298-A1 | NOVEL OPIOID COMPOUNDS AND USES THEREOF | RHODES TECHNOLOGIES (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20190187914-A9 | Processes for Making Opioids Including 14-Hydroxycodeinone and 14-Hydroxymorphinone | MACFARLAN SMITH LIMITED (GB) | 2019-06-20 | — | — | US | disclosed |
| US-10324632-B2 | Processes for making opioids including 14-hydroxycodeinone and 14-hydroxymorphinone | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2019-06-18 | — | — | US | disclosed |
| US-10226456-B2 | Methods and compositions for preventing opioid abuse | 3ST RESEARCH LLC (US) | 2019-03-12 | — | — | US | disclosed |
| EP-3024834-B1 | PREPARATION OF SATURATED KETONE MORPHINAN COMPOUNDS BY CATALYTIC ISOMERISATION | CAMBREX CHARLES CITY INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20180107407-A1 | Processes for Making Opioids Including 14-Hydroxycodeinone and 14-Hydroxymorphinone | JOHNSON MATTHEY PLC (GB) | 2018-04-19 | — | — | US | disclosed |
| EP-2373171-B1 | FREQUENCY MODULATED DRUG DELIVERY (FMDD) | SYNTHONICS INC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2580201-B1 | TRANSITION METAL-CATALYZED PROCESSES FOR THE PREPARATION OF N-ALLYL COMPOUNDS AND USE THEREOF | RHODES TECH (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-08 | — | — | US | disclosed |
| US-9624232-B2 | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof | RHODES TECHNOLOGIES (US) | 2017-04-18 | — | — | US | disclosed |
| US-20120277256-A1 | FREQUENCY MODULATED DRUG DELIVERY (FMDD) | SYNTHONICS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8236787-B2 | Frequency modulated drug delivery (FMDD) | SYNTHONICS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100144587-A1 | Frequency modulated drug delivery (FMDD) | SYNTHONICS, INC. | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226456-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20100144587-A1 | Frequency modulated drug delivery (FMDD) | FCGR3B, FCGR2A, LDLR | OPRM1 2045/4885OPRD1 1792/4885OPRK1 2847/4885 |
| US-20210061815-A1 | NOVEL OPIOID COMPOUNDS AND USES THEREOF | OPRL1, OPRK1, OPRD1 | OPRM1 4/4885OPRD1 3/4885OPRK1 2/4885 |
| US-10695342-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20200199134-A1 | PROCESS FOR IMPROVED OXYCODONE SYNTHESIS | OPRD1, OPRK1, HPD | OPRM1 8/4885OPRD1 1/4885OPRK1 2/4885 |
| US-10844072-B2 | Process for improved oxycodone synthesis | OPRD1, OPRK1, HPD | OPRM1 8/4885OPRD1 1/4885OPRK1 2/4885 |
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.